A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
收藏DataCite Commons2026-04-09 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009372/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to show that subcutaneous (SC) administration of daratumumab
co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to
intravenous (IV) administration of daratumumab (Dara IV) in terms of the overall response
rate (ORR) and maximum trough concentration (Ctrough).
提供机构：
Vivli
创建时间：
2023-10-17
